Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Immix Biopharma, Inc.NASDAQ: IMMX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How IMMX compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
IMMX Competitors
Revenue for IMMX and competitors
Company Period LTM YoY 3-year CAGR
NRIXNurix Therapeutics, Inc.LTM Aug 2026$701.94M USD+738.8%+29.5%
MGNXMacroGenics, Inc.LTM Mar 2026$157.08M USD+3.1%-0.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$117M USD-55.3%+30.2%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$35.54M USD-75.9%+12.8%
IMMPImmutep LimitedFY2025A$5.04M AUD+31.3%+209.4%
CRDFCardiff Oncology, Inc.LTM Mar 2026$525K USD-10.7%+15.4%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$112K USD-95.7%-14.0%
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 USD——
ABVXAbivax S.A.FY2025€0 EUR——
IMUXImmunic, Inc.LTM Mar 2026$0 USD——
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY-100.0%—
Peer median (excluding IMMX) —-33.0%+15.4%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000364.5K
Gross Profit0000(364.5K)
Gross Margin—————
Research & Development126.53K4.2M8.74M11.29M16.26M
Selling, General & Admin1.23M4.02M7.41M11.38M13.7M
Operating Expenses1.35M8.22M16.14M22.67M26.85M
Depreciation & Amortization2.47K2.14K5.47K115.39K364.5K
EBITDA(24.2M)(8.22M)(15.56M)(21.54M)(29.04M)
EBITDA Margin—————
Operating Income(1.35M)(8.22M)(16.14M)(22.67M)(27.21M)
Operating Margin—————
Interest Income00572.01K1.02M555.53K
Interest Expense179.85K497000
Other Income / Expenses(23.03M)(497)572.01K1.02M(2.19M)
Income Before Tax(24.38M)(8.22M)(15.57M)(21.66M)(29.4M)
Pre-Tax Margin—————
Income Tax Expense6.01K10.27K26.42K41.04K37.72K
Net Income(24.38M)(8.23M)(15.43M)(21.61M)(29.44M)
Net Margin—————
EPS (Basic)(6.64)(0.59)(0.89)(0.76)(0.89)
EPS (Diluted)(6.64)(0.59)(0.89)(0.76)(0.89)
Weighted Avg Shares3.67M13.89M17.34M28.29M32.97M
Weighted Avg Shares (Diluted)3.67M13.89M17.34M28.29M32.97M

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.